Zoetis

Zoetis Equity

The The Equity of Zoetis (ZTS) as of Oct 18, 2026 is 3.33 B USD. In the previous year, The Equity was 4.77 B USD — a change of -30.17% (lower).

Equity

3.33 BUSD

YoY

-30.17%

Last updated:

In 2025, Zoetis's equity was 3.33 B USD, a -30.17% increase from the 4.77 B USD equity in the previous year.

The Zoetis Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
2.19 B USD
Jan 1, 2019
2.71 B USD
Jan 1, 2020
3.77 B USD
Jan 1, 2021
4.54 B USD
Jan 1, 2022
4.41 B USD
Jan 1, 2023
5.00 B USD
Jan 1, 2024
4.77 B USD
Jan 1, 2025
3.33 B USD
The Zoetis Equity history
YEAREquityYoY
3.33 BUSD-30.17%
4.77 BUSD-4.54%
5.00 BUSD+13.44%
4.41 BUSD-3.04%
4.54 BUSD+20.54%
3.77 BUSD+39.18%
2.71 BUSD+23.94%
2.19 BUSD+22.34%
1.79 BUSD+19.15%
1.50 BUSD+40.36%
1.07 BUSD-18.54%
1.31 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zoetis Stock analysis

What does Zoetis do? Zoetis Inc. is a leading company in the development and marketing of animal health technology and solutions. The company specializes in innovative products for animals such as dairy cattle, pigs, poultry, dogs, cats, and horses. Zoetis was founded in 1952 as a subsidiary of Pfizer and operated as Pfizer Animal Health. In 2013, the company was finally spun off from Pfizer and became Zoetis Inc. Zoetis focuses on the development, manufacturing, and marketing of products for livestock and pets, including vaccines, pharmaceuticals, biological therapies, and diagnostics. The company operates globally and has its headquarters in Parsippany, New Jersey. Zoetis' business model consists of various business segments divided into animal categories: cattle, pigs, poultry, pets, and horses. Each of these business segments offers specialized solutions for animal owners and veterinarians. In the cattle products segment, Zoetis offers products for dairy cows, beef cattle, and calves. They also provide a variety of prevention and treatment solutions for major animal health issues such as mastitis, reproductive disorders, and respiratory problems. In the swine segment, Zoetis offers prevention and treatment solutions for infectious diseases and parasite control. They also provide products for promoting swine health and weight gain. In the poultry segment, Zoetis offers solutions for the prevention and treatment of infectious diseases. The company's products aim to improve animal health, productivity, and efficiency. Zoetis also offers products for the pet segment, including vaccines, pharmaceuticals, and therapies for dogs, cats, and other pets. Here, the company also provides solutions for major health issues such as heart diseases, pain management, and parasite control. In the horse segment, Zoetis offers solutions for the prevention and treatment of diseases such as equine rhinopneumonia, worm infestations, and arthritis. They also provide products for promoting horse health and performance. Zoetis is known for a variety of innovative products used by animal owners and veterinarians worldwide. One example is ScourGuard® 4KC, a vaccine that protects calves from diarrheal diseases caused by common bacteria. This vaccine has already proven to be highly effective in controlling bowel diseases in calves. Zoetis has also developed and marketed the first FDA-approved product for pain management in dogs (Rimadyl®), as well as the first licensed product for the treatment of giardia in dogs (Panacur®). In summary, Zoetis, as a global leader in the animal health industry, puts innovation and quality at the forefront. With a wide range of products and solutions in various animal categories, Zoetis is a key player in the animal health industry. Zoetis is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Zoetis's Equity

Zoetis's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Zoetis's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Zoetis's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Zoetis's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Zoetis’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Zoetis stock

The Equity of Zoetis is 3.33 B USD in 2025.

The Equity of Zoetis changed from 4.77 B USD to 3.33 B USD, representing a -30.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Zoetis since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Zoetis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Zoetis

All Key Metrics — Zoetis